瑞德西韦成首个FDA获批新冠药物 吉利德盘後股价涨7%
美国药厂吉利德(Gilead)(GILD.US)的抗病毒药物瑞德西韦(Remdesivir)成为首个获美国食品及药物管理局(FDA)批准的治疗新型冠状病毒药物。
在消息公布後,吉利德股价於盘後升7.1%。
瑞德西韦是美国总统特朗普感染新型冠状病毒期间所使用的药物之一,美国国家卫生研究院(NIH)的研究显示,瑞德西韦可令感染者的住院时间缩减五日。不过上周世卫(WHO)称,瑞德西韦对患者的住院时间或存活机会没有实质性影响,不过该研究尚未得到外部专家的核实。
瑞德西韦将以Veklury品牌出售,为期五日的治疗费用为3,120美元。吉利德表示,目前存量可应付美国的需求,到本月底则可满足全球的需求,而该药物亦已在另外约50个国家或地区获得当地监管部门的批准或临时授权。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.